6 research outputs found
Effect of olive oil consumption on cardiovascular disease, cancer, type 2 diabetes, and all-cause mortality: A systematic review and meta-analysis
Background: Some large prospective studies on olive oil consumption and risk of chronic disease sug-
gested protective effects.
Objective: We conducted an outcome-wide systematic review and meta-analysis of prospective cohort
studies and randomized controlled trials (RCT) assessing the association between olive oil consumption
and the primary risk of 4 different outcomes: cardiovascular disease (CVD), cancer, type 2 diabetes (T2D)
or all-cause mortality through January 2022.
Methods: Thirty-six studies were included in the systematic review and twenty-seven studies (24 pro-
spective cohorts and 3 different reports from one RCT) were assessed in 4 quantitative random-effects
meta-analyses. They included a total of 806,203 participants with 49,223 CVD events; 1,285,064 par-
ticipants with 58,892 incident cases of cancer; 680,239 participants with 13,389 incident cases of T2D;
and 733,420 participants with 174,081 deaths. Olive oil consumption was most frequently measured with
validated food frequency questionnaires. Studies follow-up ranged between 3.7 and 28 years.
Results: A 16% reduced risk of CVD (relative risk [RR]: 0.84; 95% confidence interval [CI]: 0.76 to 0.94),
standardized for every additional olive oil consumption of 25 g/d was found. No significant association
with cancer risk was observed (RR: 0.94; 95% CI: 0.86 to 1.03, per 25 g/d). Olive oil consumption was
associated with a 22% lower relative risk of T2D (RR: 0.78; 95% CI: 0.69 to 0.87, per 25 g/d) without
evidence of heterogeneity. Similarly, it was inversely associated with all-cause mortality (RR: 0.89; 95%
CI: 0.85 to 0.93, per 25 g/d). Only the results for T2D were homogeneous. Specific sources of hetero-
geneity for the other 3 outcomes were not always apparent.
Conclusions: Prospective studies supported a beneficial association of olive oil consumption with CVD,
T2D and all-cause mortality, but they did not show any association with cancer risk
Effect of olive oil consumption on cardiovascular disease, cancer, type 2 diabetes, and all-cause mortality: a systematic review and meta-analysis
Background: Some large prospective studies on olive oil consumption and risk of chronic disease suggested protective effects.
Objective: We conducted an outcome-wide systematic review and meta-analysis of prospective cohort studies and randomized controlled trials (RCT) assessing the association between olive oil consumption and the primary risk of 4 different outcomes: cardiovascular disease (CVD), cancer, type 2 diabetes (T2D) or all-cause mortality through January 2022.
Methods: Thirty-six studies were included in the systematic review and twenty-seven studies (24 prospective cohorts and 3 different reports from one RCT) were assessed in 4 quantitative random-effects meta-analyses. They included a total of 806,203 participants with 49,223 CVD events; 1,285,064 participants with 58,892 incident cases of cancer; 680,239 participants with 13,389 incident cases of T2D; and 733,420 participants with 174,081 deaths. Olive oil consumption was most frequently measured with validated food frequency questionnaires. Studies follow-up ranged between 3.7 and 28 years.
Results: A 16% reduced risk of CVD (relative risk [RR]: 0.84; 95% confidence interval [CI]: 0.76 to 0.94), standardized for every additional olive oil consumption of 25 g/d was found. No significant association with cancer risk was observed (RR: 0.94; 95% CI: 0.86 to 1.03, per 25 g/d). Olive oil consumption was associated with a 22% lower relative risk of T2D (RR: 0.78; 95% CI: 0.69 to 0.87, per 25 g/d) without evidence of heterogeneity. Similarly, it was inversely associated with all-cause mortality (RR: 0.89; 95% CI: 0.85 to 0.93, per 25 g/d). Only the results for T2D were homogeneous. Specific sources of heterogeneity for the other 3 outcomes were not always apparent.
Conclusions: Prospective studies supported a beneficial association of olive oil consumption with CVD, T2D and all-cause mortality, but they did not show any association with cancer risk
Corrigendum : Role of NAFLD on the health related QoL response to lifestyle in patients with metabolic syndrome: The PREDIMED plus cohort
Association between individual phenotypic features and lifestyle factors on the risk of non-alcoholic fatty liver disease in older subjects with metabolic syndrome
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, whose prevalence is growing worldwide in parallel with obesity and type 2 diabetes mellitus (T2DM) rates. This trend spreads the global burden of NAFLD due to an increase in health-care costs and a negative impact on wellbeing and the quality of life. The prevalence of NAFLD is higher in men than women in adulthood. However, this tendency changes in ageing because postmenopausal status is associated with a higher risk to develop NAFLD. Also, body fat redistribution characterized by enlarged visceral adipose tissue (VAT) leads to insulin resistance, playing a crucial role in NAFLD pathogenesis. Unhealthy lifestyle behaviours, including poor eating habits and physical inactivity, cause harmful effects on health outcomes. The associations between sex-differences, metabolic phenotype, lifestyle factors and specific bioactive compounds on risk factors and predisposition to develop NAFLD in the elderly population with a high risk of cardiovascular disease and MetS features are scarcely known. Hence, the aims of the present thesis were: 1) to evaluate sex-related differences in risk factors of NAFLD in elderly individuals; 2) to assess the relationship between VAT and insulin resistance on NAFLD risk factors; 3) to study the associations between lifestyle factors focused on adherence to the Mediterranean diet (MedDiet), dietary components, and physical activity on factors linked to NAFLD; 4) to investigate the interrelationships between some urinary metabolites associated to MedDiet with cardiometabolic and liver markers involved in NAFLD development. In Chapter 1, we found that women had an increased risk to develop NAFLD measured by the hepatic steatosis index (HSI) compared to men, suggesting the potential role of sex differences on risk factors related to NAFLD in elderly individuals. In Chapter 2, increased amounts of visceral adipose tissue (VAT) and triglyceride Glucose Index (TyG) values were associated with worsened liver status and exacerbated cardiometabolic risk factors. Besides, the TyG index could be a proxy indicator of increased deposition of VAT in women diagnosed with MetS. In Chapter 3, those individuals with greater adherence to the MedDiet and higher levels of physical activity were inversely associated with HSI related to liver steatosis state. Furthermore, higher consumption of legumes was associated with a lower risk to have increased HSI values. In Chapter 4, a healthier lipid profile and liver enzymes levels were linked to higher concentrations of urinary resveratrol metabolites, where total urine resveratrol concentration was inversely associated with the risk of having elevated liver enzymes. In summary, the findings presented in this thesis show the implications of potential sex-related differences and individual phenotype on the predisposition of NAFLD. This relationship was even more marked in individuals with an adiposopathy VAT and insulin resistance features. Notably, the TyG index could be proposed as a reliable marker of enlarged VAT deposition in women with MetS features. Another point of interest is that lifestyle modifications focused on greater adherence to the MedDiet, especially promoting the consumption of some dietary components (legumes) and bioactive compounds (resveratrol) as well as increased levels of physical activity might be considered a relevant part of a liver-healthy lifestyle in elderly individuals at high cardiovascular risk diagnosed with MetS
Effect of olive oil consumption on cardiovascular disease, cancer, type 2 diabetes, and all-cause mortality: A systematic review and meta-analysis
Background: Some large prospective studies on olive oil consumption and risk of chronic disease sug-
gested protective effects.
Objective: We conducted an outcome-wide systematic review and meta-analysis of prospective cohort
studies and randomized controlled trials (RCT) assessing the association between olive oil consumption
and the primary risk of 4 different outcomes: cardiovascular disease (CVD), cancer, type 2 diabetes (T2D)
or all-cause mortality through January 2022.
Methods: Thirty-six studies were included in the systematic review and twenty-seven studies (24 pro-
spective cohorts and 3 different reports from one RCT) were assessed in 4 quantitative random-effects
meta-analyses. They included a total of 806,203 participants with 49,223 CVD events; 1,285,064 par-
ticipants with 58,892 incident cases of cancer; 680,239 participants with 13,389 incident cases of T2D;
and 733,420 participants with 174,081 deaths. Olive oil consumption was most frequently measured with
validated food frequency questionnaires. Studies follow-up ranged between 3.7 and 28 years.
Results: A 16% reduced risk of CVD (relative risk [RR]: 0.84; 95% confidence interval [CI]: 0.76 to 0.94),
standardized for every additional olive oil consumption of 25 g/d was found. No significant association
with cancer risk was observed (RR: 0.94; 95% CI: 0.86 to 1.03, per 25 g/d). Olive oil consumption was
associated with a 22% lower relative risk of T2D (RR: 0.78; 95% CI: 0.69 to 0.87, per 25 g/d) without
evidence of heterogeneity. Similarly, it was inversely associated with all-cause mortality (RR: 0.89; 95%
CI: 0.85 to 0.93, per 25 g/d). Only the results for T2D were homogeneous. Specific sources of hetero-
geneity for the other 3 outcomes were not always apparent.
Conclusions: Prospective studies supported a beneficial association of olive oil consumption with CVD,
T2D and all-cause mortality, but they did not show any association with cancer risk
Effect of olive oil consumption on cardiovascular disease, cancer, type 2 diabetes, and all-cause mortality: a systematic review and meta-analysis
Background: Some large prospective studies on olive oil consumption and risk of chronic disease suggested protective effects.
Objective: We conducted an outcome-wide systematic review and meta-analysis of prospective cohort studies and randomized controlled trials (RCT) assessing the association between olive oil consumption and the primary risk of 4 different outcomes: cardiovascular disease (CVD), cancer, type 2 diabetes (T2D) or all-cause mortality through January 2022.
Methods: Thirty-six studies were included in the systematic review and twenty-seven studies (24 prospective cohorts and 3 different reports from one RCT) were assessed in 4 quantitative random-effects meta-analyses. They included a total of 806,203 participants with 49,223 CVD events; 1,285,064 participants with 58,892 incident cases of cancer; 680,239 participants with 13,389 incident cases of T2D; and 733,420 participants with 174,081 deaths. Olive oil consumption was most frequently measured with validated food frequency questionnaires. Studies follow-up ranged between 3.7 and 28 years.
Results: A 16% reduced risk of CVD (relative risk [RR]: 0.84; 95% confidence interval [CI]: 0.76 to 0.94), standardized for every additional olive oil consumption of 25 g/d was found. No significant association with cancer risk was observed (RR: 0.94; 95% CI: 0.86 to 1.03, per 25 g/d). Olive oil consumption was associated with a 22% lower relative risk of T2D (RR: 0.78; 95% CI: 0.69 to 0.87, per 25 g/d) without evidence of heterogeneity. Similarly, it was inversely associated with all-cause mortality (RR: 0.89; 95% CI: 0.85 to 0.93, per 25 g/d). Only the results for T2D were homogeneous. Specific sources of heterogeneity for the other 3 outcomes were not always apparent.
Conclusions: Prospective studies supported a beneficial association of olive oil consumption with CVD, T2D and all-cause mortality, but they did not show any association with cancer risk